FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or […]

…/Auszug

Fact or Fiction: 5 Myths About Dust Mites

If you’re reading this, there’s a good chance you’re one of the millions of Americans with a dust mite allergy. But how well do you know these microscopic creatures? Here’s a look at some common misconceptions about dust mites and dust mite allergy. Lesen Sie weiter auf: Fact or Fiction: 5 Myths About Dust Mites […]

…/Auszug

AAFA Offers Free Online Course for Severe Asthma

Severe ASTHMA (Asthma Symptoms, Treatment, Health Management and Activities™) Care for Adults is a FREE self-paced course that helps adults and their caregivers learn how to manage severe asthma. It explains severe and uncontrolled asthma, the impact of severe asthma, asthma management plans and severe asthma treatments. Lesen Sie weiter auf: AAFA Offers Free Online […]

…/Auszug